Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial.

Steigler A, Denham JW, Lamb DS, Spry NA, Joseph D, Matthews J, Atkinson C, Turner S, North J, Christie D, Tai KH, Wynne C.

Prostate Cancer. 2012;2012:814724. doi: 10.1155/2012/814724. Epub 2012 Dec 24.

PMID:
23320177
2.

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.

Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Matthews J, Tai KH, Spry NA, Christie D, Gleeson PS, Greer PB, D'Este C; Trans-Tasman Radiation Oncology Group 96.01 Trialists.

Lancet Oncol. 2008 Nov;9(11):1058-68. doi: 10.1016/S1470-2045(08)70236-5. Epub 2008 Oct 15.

PMID:
18929505
3.

Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer.

Hanlon AL, Horwitz EM, Hanks GE, Pollack A.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):43-52.

PMID:
14697419
4.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.

Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.

PMID:
25130995
5.
6.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.

Mayo Clin Proc. 2001 Jun;76(6):576-81.

PMID:
11393495
7.

Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?

Denham JW, Steigler A, Kumar M, Lamb DS, Joseph D, Spry NA, Tai KH, Atkinson C, Turner S, Greer PB, Gleeson PS, D'Este C.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1008-12. doi: 10.1016/j.ijrobp.2008.12.085. Epub 2009 Jul 4.

PMID:
19577859
8.

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C.

Lancet Oncol. 2011 May;12(5):451-9. doi: 10.1016/S1470-2045(11)70063-8.

PMID:
21440505
9.

Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.

Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE.

Cancer. 2003 Feb 15;97(4):1127-33.

PMID:
12569615
10.

PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.

Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, Montorsi F, Messa C.

Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1106-16. doi: 10.1007/s00259-010-1403-7. Epub 2010 Mar 20.

PMID:
20306038
11.

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.

Hanlon AL, Diratzouian H, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):297-303.

PMID:
12023133
12.

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.

Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM; Radiation Therapy Oncology Group Protocol 92-02.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1064-71. Epub 2006 Sep 18.

PMID:
16979837
13.

Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy.

Cheney MD, Zhang D, Chen MH, Loffredo MJ, Richie JP, D'Amico AV.

Clin Genitourin Cancer. 2015 Aug;13(4):338-43. doi: 10.1016/j.clgc.2015.02.012. Epub 2015 Mar 5.

PMID:
25862320
14.

A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.

Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY.

Radiat Oncol. 2013 Jul 8;8:170. doi: 10.1186/1748-717X-8-170.

PMID:
23835115
15.

Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.

Chang SL, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC Jr.

Urology. 2010 Feb;75(2):439-44. doi: 10.1016/j.urology.2009.06.089. Epub 2009 Oct 12.

PMID:
19819536
16.

Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.

D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW.

JAMA. 2000 Sep 13;284(10):1280-3.

PMID:
10979115
17.

Markers and meaning of primary treatment failure.

Swindle PW, Kattan MW, Scardino PT.

Urol Clin North Am. 2003 May;30(2):377-401. Review.

PMID:
12735513
18.

Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Jun;67(6):1160-7. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.

PMID:
25301759
19.

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW.

JAMA. 2005 Jul 27;294(4):433-9.

PMID:
16046649
20.

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.

Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai KH, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P.

Lancet Oncol. 2012 Dec;13(12):1260-70. doi: 10.1016/S1470-2045(12)70423-0. Epub 2012 Nov 12. Erratum in: Lancet Oncol. 2014 Sep;15(10):e417. Dosage error in article text.

PMID:
23151431

Supplemental Content

Support Center